Clinical efficacy observation of alprostadil combined with butylphthalide in treatment of cerebral infarction / 中国现代医生

ABSTRACT

Objective To investigate the clinical effects of alprostadil combined with butylphthalide in treatment of cerebral infarction. Methods Ninety-four patients with cerebral infarction treated in our hospital from November 2011 to January 2014 were selected as the study subjects and randomly divided into the control group with 47 patients and the observation group with 47 patients. The control group received alprostadil treatment and the observation group re-ceived alprostadil combined with butylphthalide treatment. The changes of treatment efficacy and NIHSS scores, im-provement of quality of life, changes of laboratory parameters and safety of the two groups were observed. Results The observation group had significantly higher total effective treatment rate than the control group (P<0.05). The two groups were not significantly different in the NIHSS score before treatment (P>0.05); both groups improved gradually after 7 days of treatment and recovered well after 2 weeks; the observation group had significantly better recovery effect than the control group(P<0.05). After treatment, the quality of life of both groups was evaluated, which showed that the obser-vation group had significantly higher quality of life than the control group(P<0.05). The two groups were not significantly different in PT (P>0.05), and the observation group had significantly higher APTT and PLT and significantly lower Fb than the control group, with statistically significant differences (P<0.05). The incidence of complications of the observa-tion group was 8.51%, which was significantly lower than the 19.15% of the control group, with statistically significant difference (P<0.05). Conclusion Both alprostadil and butylphthalide have good treatment effects on cerebral infarction and their combination generates a synergistic effect, which can rapidly improve neurological function, enhance efficacy and help improve the patients' quality of life, thereby worthy of clinical promotion.